By Colin Kellaher
Zevra Therapeutics has inked a deal to sell its Food and Drug Administration priority-review voucher to an undisclosed buyer for gross proceeds of $150 million.
Zevra, which won the voucher upon FDA approval of its Miplyffa drug for the rare neurodegenerative disorder Niemann-Pick disease type C, on Thursday said it expects to complete the sale within 30 to 45 days.
The FDA awards the vouchers upon approval of drugs previously granted rare-pediatric-disease designation, and they can be used to obtain priority review for another drug or sold to other companies. Acadia Pharmaceuticals and PTC Therapeutics last year struck deals to sell vouchers for $150 million apiece.
Zevra, a Celebration, Fla., rare-disease company, said it will use the sale proceeds to support the commercial launches of its Miplyffa and Olpruva drugs and to advance its pipeline of product candidates.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 27, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。